Targeting SR-BI for cancer diagnostics, imaging and therapy

Frontiers in Pharmacology

Volumn 7, Issue SEP, 2016, Pages

  Rajora, Maneesha A ^a,b   Zheng, Gang ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomarkers; Cancer imaging; Cancer therapy; HDL; Nanomimetics; Scavenger receptor BI

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; ANTIGEN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C2; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BACTERIOCHLORIN; DICHLOROACETIC ACID; DOXORUBICIN; EPOTHILONE B; GAMBOGIC ACID; HIGH DENSITY LIPOPROTEIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; NANOPARTICLE; OVALBUMIN ANTIGEN; OXIDIZED LOW DENSITY LIPOPROTEIN; PACLITAXEL; PH SENSITIVE NANOPARTICLE; PORPHYRIN; PROTEIN BCL 2; SCAVENGER RECEPTOR BI; SERUM AMYLOID A; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADRENAL TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; DRUG DELIVERY SYSTEM; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; HUMAN; IMAGING; IMMUNOTHERAPY; LYMPHOMA; METASTASIS; NASOPHARYNX CARCINOMA; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PROSTATE BONE METASTASIS; PROSTATE CANCER; SHORT SURVEY; TESTIS CANCER; UPREGULATION;

EID: 84992473919     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00326     Document Type: Short Survey

References (78)

1. Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., and Krieger, M. (1996). Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271, 518-520. doi: 10.1126/science.271.5248.518
2. Arenas, M. I., Lobo, M. V. T., Caso, E., Huerta, L., Paniagua, R., and Martiìn-Hidalgo, M. A. (2004). Normal and pathological human testes express hormone-sensitive lipase and the lipid receptors CLA-1/SR-BI and CD36. Hum. Pathol. 35, 34-42. doi: 10.1016/j.humpath.2003.08.015
3. Baranova, I. N., Vishnyakova, T. G., Bocharov, A. V., Kurlander, R., Chen, Z., Kimelman, M. L., et al. (2005). Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J. Biol. Chem. 280, 8031-8040. doi: 10.1074/jbc.M405009200
4. Calvo, D., Gómez-Coronado, D., Lasunción, M. A., and Vega, M. A. (1997). CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17, 2341-2349. doi: 10.1161/01.ATV.17.11.2341
5. Cao, W., Ng, K. K., Corbin, I., Zhang, Z., Ding, L., Chen, J., et al. (2009). Synthesis and evaluation of a stable bacteriochlorophyll-analog and its incorporation into high-density lipoprotein nanoparticles for tumor imaging. Bioconjug. Chem. 20, 2023-2031. doi: 10.1021/bc900404y
6. Cao, W. M., Murao, K., Imachi, H., Yu, X., Abe, H., Yamauchi, A., et al. (2004). A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 64, 1515-1520. doi: 10.1158/0008-5472.CAN-03-0675
7. Cruz, P. M., Mo, H., McConathy, W. J., Sabnis, N., and Lacko, A. G. (2013). The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front. Pharmacol. 4:119. doi: 10.3389/fphar.2013.00119
8. Cui, L., Lin, Q., Jin, C. S., Jiang, W., Huang, H., Ding, L., et al. (2015). A PEGylation-free biomimetic porphyrin nanoplatform for personalized cancer theranostics. ACS Nano 9, 4484-4495. doi: 10.1021/acsnano.5b01077
9. de Gonzalo-Calvo, D., Lopez-Vilaro, L., Nasarre, L., Perez-Olabarria, M., Vazquez, T., Escuin, D., et al. (2015). Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study. BMC Cancer 15:460. doi: 10.1186/s12885-015-1469-5
10. Dessì, S., Batetta, B., Pulisci, D., Spano, O., Anchisi, C., Tessitore, L., et al. (1994). Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer. Cancer 73, 253-258. doi: 10.1002/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F
11. Devi, G. R. (2006). siRNA-based approaches in cancer therapy. Cancer Gene Ther. 13, 819-829. doi: 10.1038/sj.cgt.7700931
12. Ding, Y., Wang, Y., Opoku-Damoah, Y., Wang, C., Shen, L., Yin, L., et al. (2015). Dual-functional bio-derived nanoparticulates for apoptotic antitumor therapy. Biomaterials 72, 90-103. doi: 10.1016/j.biomaterials.2015.08.051
13. Ding, Y., Wang, Y., Zhou, J., Gu, X., Wang, W., Liu, C., et al. (2014). Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis. Biomaterials 35, 7214-7227. doi: 10.1016/j.biomaterials.2014.05.009
14. Fletcher, N. F., Yang, J. P., Farquhar, M. J., Hu, K., Davis, C., He, Q., et al. (2010). Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology 139, 1365-1374. doi: 10.1053/j.gastro.2010.06.008
15. Gillies, R. J., Schornack, P. A., Secomb, T. W., and Raghunand, N. (1999). Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1, 197-207. doi: 10.1038/sj.neo.7900037
16. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70. doi: 10.1016/S0092-8674(00)81683-9
17. Hrzenjak, A., Reicher, H., Wintersperger, A., Steinecker-Frohnwieser, B., Sedlmayr, P., Schmidt, H., et al. (2004). Inhibition of lung carcinoma cell growth by high density lipoprotein-associated alpha-tocopheryl-succinate. Cell. Mol. Life Sci. 61, 1520-1530. doi: 10.1007/s00018-004-4101-4
18. Husemann, J., and Silverstein, S. C. (2001). Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain. Am. J. Pathol. 158, 825-832. doi: 10.1016/S0002-9440(10)64030-8
19. Imachi, H., Murao, K., Cao, W., Tada, S., Taminato, T., Wong, N. C., et al. (2003). Expression of human scavenger receptor B1 on and in human platelets. Arterioscler. Thromb. Vasc. Biol. 23, 898-904. doi: 10.1161/01.ATV.0000067429.46333.7B
20. Imachi, H., Murao, K., Sayo, Y., Hosokawa, H., Sato, M., Niimi, M., et al. (1999). Evidence for a potential role for HDL as an important source of cholesterol in human adrenocortical tumors via the CLA-1 pathway. Endocr. J. 46, 27-34. doi: 10.1507/endocrj.46.27
21. Ji, Y., Jian, B., Wang, N., Sun, Y., Moya, M. L., Phillips, M. C., et al. (1997). Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J. Biol. Chem. 272:20982. doi: 10.1074/jbc.272.34.20982
22. Julovi, S. M., Xue, A., Thanh, L. T., Gill, A. J., Bulanadi, J. C., Patel, M., et al. (2016). Apolipoprotein A-II plus lipid emulsion enhance cell growth via SR-B1 and target pancreatic cancer in vitro and in vivo. PLoS ONE 11:e0151475. doi: 10.1371/journal.pone.0151475
23. Kingwell, B. A., and Chapman, M. J. (2013). Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease. Circulation 128, 1112-1121. doi: 10.1161/CIRCULATIONAHA.113.002683
24. Krieger, M. (1999). Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu. Rev. Biochem. 68, 523-528. doi: 10.1146/annurev.biochem.68.1.523
25. Lacko, A. G., Nair, M., Paranjape, S., Johnson, S., and McConathy, W. J. (2002). High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 22, 2045-2049.
26. Lee, J.-C., Kong, B.-J., Shin, J. Y., Shin, J., Oh, J.-S., Cho, J. Y., et al. (2015). A pH-responsive high density lipoprotein-like nanoparticle of epothilone B. Biotechnol. Bioprocess. Eng. 20, 249-258. doi: 10.1007/s12257-014-0368-y
27. Leon, C. G., Locke, J. A., Adomat, H. H., Etinger, S. L., Twiddy, A. L., Neumann, R. D., et al. (2010). Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70, 390-400. doi: 10.1002/pros.21072
28. Liadaki, K. N., Liu, T., Xu, S., Ishida, B. Y., Duchateaux, P. N., Krieger, J. P., et al. (2000). Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J. Biol. Chem. 275, 21262-21271. doi: 10.1074/jbc.M002310200
29. Lin, Q., Chen, J., Jin, H., Ng, K. K., Yang, M., Cao, W., et al. (2012). Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine (Lond) 7, 1813-1828. doi: 10.2217/nnm.12.73
30. Lin, Q., Chen, J., Ng, K. K., Cao, W., Zhang, Z., and Zheng, G. (2014a). Imaging the cytosolic drug delivery mechanism of HDL-like nanoparticles. Pharm. Res. 31, 1438-1449. doi: 10.1007/s11095-013-1046-z
31. Lin, Q., Jin, C. S., Huang, H., Ding, L., Zhang, Z., Chen, J., et al. (2014b). Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model. Small 10, 3072-3082. doi: 10.1002/smll.201303842
32. Lobo, M. V., Huerta, L., Ruiz-Velasco, N., Teixeiro, E., de la Cueva, P., Celdrán, A., et al. (2001). Localization of the lipid receptors CD36 and CLA-1/SR-BI in the human gastrointestinal tract: towards the identification of receptors mediating the intestinal absorption of dietary lipids. J. Histochem. Cytochem. 49, 1253-1260. doi: 10.1177/002215540104901007
33. Lu, H., Zhang, H., Zhang, D., Lu, H., and Ma, D. (2015). A biocompatible reconstituted high-density lipoprotein nano-system as a probe for lung cancer detection. Med. Sci. Monit. 21, 2726-2733. doi: 10.12659/MSM.895255
34. McConathy, W. J., Nair, M. P., Paranjape, S., Mooberry, L., and Lacko, A. G. (2008). Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 19, 183-188. doi: 10.1097/CAD.0b013e3282f1da86
35. McConathy, W. J., Paranjape, S., Mooberry, L., Buttreddy, S., Nair, M., and Lacko, A. G. (2011). Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). Drug Deliv. Transl. Res. 1, 113-120. doi: 10.1007/s13346-010-0012-0
36. Mooberry, L. K., Nair, M., Paranjape, S., McConathy, W. J., and Lacko, A. G. (2010). Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target. 18, 53-58. doi: 10.3109/10611860903156419
37. Mulik, R. S., Bing, C., Ladouceur-Wodzak, M., Munaweera, I., Chopra, R., and Corbin, I. R. (2016). Localized delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat brain using focused ultrasound. Biomaterials 83, 257-268. doi: 10.1016/j.biomaterials.2016.01.021
38. Ng, K. K., Lovell, J. F., Vedadi, A., Hajian, T., and Zheng, G. (2013). Self-assembled porphyrin nanodiscs with structure-dependent activation for phototherapy and photodiagnostic applications. ACS Nano 7, 3484-3490. doi: 10.1021/nn400418y
39. Ng, K. K., Lovell, J. F., and Zheng, G. (2011). Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 44, 1105-1113. doi: 10.1021/ar200017e
40. Nichols, J. W., and Bae, Y. H. (2012). Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 7, 606-618. doi: 10.1016/j.nantod.2012.10.010
41. Oehler, V. G., Yeung, K. Y., Choi, Y. E., Bumgarner, R. E., Raftery, A. E., and Radich, J. P. (2009). The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 114, 3292-3298. doi: 10.1182/blood-2009-03-212969
42. Oh, Y. K., and Park, T. G. (2009). siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 61, 850-862. doi: 10.1016/j.addr.2009.04.018
43. Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., and Sood, A. K. (2011). RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11, 59-67. doi: 10.1038/nrc2966
44. Petrocca, F., and Lieberman, J. (2011). Promise and challenge of RNA interference-based therapy for cancer. J. Clin. Oncol. 29, 747-754. doi: 10.1200/JCO.2009.27.6287
45. Pilon, A., Martin, G., Bultel-Brienne, S., Junquero, D., Delhon, A., Fruchart, J.-C., et al. (2003). Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. Biochim. Biophys. Acta. 1631, 218-228. doi: 10.1016/s1388-1981(03)00020-9
46. Pussinen, P. J., Karten, B., Wintersperger, A., Reicher, H., McLean, M., Malle, E., et al. (2000). The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. Biochem. J. 349, 559-566. doi: 10.1042/bj3490559
47. Qian, Y., Jin, H., Qiao, S., Dai, Y., Huang, C., Lu, L., et al. (2016). Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy. Biomaterials 98, 171-183. doi: 10.1016/j.biomaterials.2016.05.008
48. Rao, R. M. (2002). Differential regulation of steroid hormone biosynthesis in R2C and MA-10 Leydig tumor cells: role of SR-B1-mediated selective cholesteryl ester transport. Biol. Reprod. 68, 114-121. doi: 10.1095/biolreprod.102.007518
49. Reboul, E., Klein, A., Bietrix, F., Gleize, B., Malezet-Desmoulins, C., Schneider, M., et al. (2006). Scavenger receptor class B type I (SR-BI) is involved in vitamin E transport across the enterocyte. J. Biol. Chem. 281, 4739-4745. doi: 10.1074/jbc.M509042200
50. Rodrigueza, W. V., Thuahnai, S. T., Temel, R. E., Lund-Katz, S., Phillips, M. C., and Williams, D. L. (1999). Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells. J. Biol. Chem. 274, 20344-20350. doi: 10.1074/jbc.274.29.20344
51. Schorghofer, D., Kinslechner, K., Preitschopf, A., Schutz, B., Rohrl, C., Hengstschlager, M., et al. (2015). The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence. Reprod. Biol. Endocrinol. 13:88. doi: 10.1186/s12958-015-0087-z
52. Shahzad, M. M. K., Mangala, L. S., Han, H. D., Lu, C., Bottsford-Miller, J., Nishimura, M., et al. (2011). Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13, 309-319. doi: 10.1593/neo.101372
53. Shin, J. Y., Yang, Y., Heo, P., Lee, J. C., Kong, B., Cho, J. Y., et al. (2012). pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. Int. J. Nanomedicine 7, 2805-2816. doi: 10.2147/IJN.S29817
54. Simonsen, J. B. (2016). Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform-a detailed survey of rHDL particles ranging from biophysical properties to clinical implications. Nanomedicine doi: 10.1016/j.nano.2016.05.009 [Epub ahead of print].
55. Su, F., Kozak, K. R., Imaizumi, S., Gao, F., Amneus, M. W., Grijalva, V., et al. (2010). Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 107, 19997-20002. doi: 10.1073/pnas.1009010107
56. Swyer, G. I. M. (1942). The cholesterol content of normal and enlarged prostates. Cancer Res. 2, 372-375.
57. Thaxton, C. S., Rink, J. S., Naha, P. C., and Cormode, D. P. (2016). Lipoproteins and lipoprotein mimetics for imaging and drug delivery. Adv. Drug Deliv. Rev doi: 10.1016/j.addr.2016.04.020 [Epub ahead of print].
58. Thuahnai, S. T., Lund-Katz, S., Anantharamaiah, G. M., Williams, D. L., and Phillips, M. C. (2003). A quantitative analysis of apolipoprotein binding to SR-BI: multiple binding sites for lipid-free and lipid-associated apolipoproteins. J. Lipid Res. 44, 1132-1142. doi: 10.1194/jlr.M200429-JLR200
59. Thysell, E., Surowiec, I., Hörnberg, E., Crnalic, S., Widmark, A., Johansson, A. I., et al. (2010). Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS ONE 5:e14175. doi: 10.1371/journal.pone.0014175
60. Tripathy, S., Vinokour, E., McMahon, K. M., Volpert, O. V., and Thaxton, C. S. (2014). High-density lipoprotein nanoparticles deliver RNAi to endothelial cells to inhibit angiogenesis. Part. Part. Syst. Charact. 31, 1141-1150. doi: 10.1002/ppsc.201400036
61. Twiddy, A. L., Cox, M. E., and Wasan, K. M. (2012). Knockdown of scavenger receptor class B type I reduces prostate specific antigen secretion and viability of prostate cancer cells. Prostate 72, 955-965. doi: 10.1002/pros.21499
62. Vishnyakova, T. G., Bocharov, A. V., Baranova, I. N., Chen, Z., Remaley, A. T., Csako, G., et al. (2003). Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J. Biol. Chem. 278, 22771-22780. doi: 10.1074/jbc.M211032200
63. Wadsack, C., Hirschmugl, B., Hammer, A., Levak-Frank, S., Kozarsky, K. F., Sattler, W., et al. (2003). Scavenger receptor class B, type I on non-malignant and malignant human epithelial cells mediates cholesteryl ester-uptake from high density lipoproteins. Int. J. Biochem. Cell Biol. 35, 441-454. doi: 10.1016/S1357-2725(02)00272-8
64. Whitehead, K. A., Langer, R., and Anderson, D. G. (2009). Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138. doi: 10.1038/nrd2742
65. Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149-1157. doi: 10.1038/nbt1339
66. Xu, S., Laccotripe, M., Huang, X., Rigotti, A., Zannis, V. I., and Krieger, M. (1997). Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J. Lipid Res. 38, 1289-1298.
67. Yang, M., Chen, J., Cao, W., Ding, L., Ng, K. K., Jin, H., et al. (2011a). Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide-phospholipid nanoscaffold. Nanomedicine (Lond) 6, 631-641. doi: 10.2217/nnm.11.10
68. Yang, M., Jin, H., Chen, J., Ding, L., Ng, K. K., Lin, Q., et al. (2011b). Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small 7, 568-573. doi: 10.1002/smll.201001589
69. Yang, S., Damiano, M. G., Zhang, H., Tripathy, S., Luthi, A. J., Rink, J. S., et al. (2013). Biomimetic, synthetic HDL nanostructures for lymphoma. Proc. Natl. Acad. Sci. U.S.A. 110, 2511-2516. doi: 10.1073/pnas.1213657110
70. Yuan, B., Wu, C., Wang, X., Wang, D., Liu, H., Guo, L., et al. (2016). High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer. Tumour Biol. 37, 3581-3588. doi: 10.1007/s13277-015-4141-4
71. Yuan, Y., Wang, W., Wang, B., Zhu, H., Zhang, B., and Feng, M. (2013). Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J. Drug Target. 21, 367-374. doi: 10.3109/1061186X.2012.757769
72. Zamanian-Daryoush, M., and DiDonato, J. A. (2015). Apolipoprotein A-I and Cancer. Front. Pharmacol. 6:265. doi: 10.3389/fphar.2015.00265
73. Zhang, F., Li, M., Su, Y., Zhou, J., and Wang, W. (2016). A dual-targeting drug co-delivery system for tumor chemo-and gene combined therapy. Mater. Sci. Eng. C Mater. Biol. Appl. 64, 208-218. doi: 10.1016/j.msec.2016.03.083
74. Zhang, Z., Cao, W., Jin, H., Lovell, J. F., Yang, M., Ding, L., et al. (2009). Biomimetic nanocarrier for direct cytosolic drug delivery. Angew. Chem. Int. Ed. Engl. 48, 9171-9175. doi: 10.1002/anie.200903112
75. Zhang, Z., Chen, J., Ding, L., Jin, H., Lovell, J. F., Corbin, I. R., et al. (2010). HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6, 430-437. doi: 10.1002/smll.200901515
76. Zheng, G., Chen, J., Stefflova, K., Jarvi, M., Li, H., and Wilson, B. C. (2007). Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc. Natl. Acad. Sci. U.S.A. 104, 8989-8994. doi: 10.1073/pnas.0611142104
77. Zheng, Y., Liu, Y., Jin, H., Pan, S., Qian, Y., Huang, C., et al. (2013). Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics 3, 477-486. doi: 10.7150/thno.6617
78. Zuckerman, J. E., and Davis, M. E. (2015). Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 14, 843-856. doi: 10.1038/nrd4685